Lavipharm announces the launch of its proprietary transdermal nitroglycerine patch in the Canadian market by the international pharmaceutical company Novartis. Under the terms of the agreement, Lavipharm has licensed to Novartis the rights to exclusively distribute and sell the product under Lavipharm's international trademark Trinipatch and is providing finished product from its manufacturing facilities in Greece.

Lavipharm's Chairman and CEO Dr. Athanase Lavidas noted: "Novartis is a strategic partner for Lavipharm, as this is not the first time both companies join forces; Novartis has been selling Trinipatch' in the Italian market since 1995".
Trinipatch, developed by Lavipharm, is a nitroglycerine transdermal delivery system indicated in Canada for the prevention of anginal attacks in patients with stable angina pectoris associated with coronary artery disease. Until today, it is successfully marketed in many European countries, such as Belgium, France, and Spain by some of the most important pharmaceutical companies. Lavipharm has also received approval to market the product in Brazil, Israel, Sweden, Norway and Cyprus and is currently under discussions for its future commercialisation.
Transdermal Drug Delivery Systems (TDDS) are among the most popular drug delivery methods. TDDSs are patches placed on specific areas of the skin and enable certain drug substances to penetrate through the skin layers into the blood stream or the desired site. Compared to other dosage forms, this controlled delivery provides many advantages. On the other hand, the nitrate market is one of the largest internationally. Trinipatch, as a third generation transdermal system, has a stable therapeutic effect and has been designed to provide continuous and controlled release of nitroglycerin through contact with the skin.
Lavipharm, founded in 1911, is an integrated pharmaceutical Group of Companies engaged in the research, development, manufacturing, marketing, sales, and distribution of pharmaceutical, dermocosmetic and healthcare products in Greece with strong international activity. Lavipharm S.A., the mother company, is listed on the Athens Stock Exchange (ASE: LAVI). For more information, please visit Lavipharm's website at www.lavipharm.com.